New antipsychotic agents: Emerging clinical profiles

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 1, 1999, Pages 12-17

  Buckley, Peter F ^a,b  

^a ODMH Northcoast Behavioral Healthcare   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZOTEPINE;

AGGRESSIVENESS; BEHAVIOR DISORDER; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; LONG TERM CARE; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

AGGRESSION; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; COMORBIDITY; COST-BENEFIT ANALYSIS; DRUG COSTS; DYSKINESIA, DRUG-INDUCED; HEALTH CARE COSTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 0033040677     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Managed Care. 1998;4:369-383
2. Kane JM. Schizophrenia. N Engl J Med 1996:334:34-41
3. Kane JM. Tardive dyskinesia. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1485-1495
4. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
5. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
6. Tollefson GD, Beasely CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophremform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
7. Arvantis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
8. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
9. Tamminga CA. The promise of new drugs for schizophrenia treatment. Can J Psychiatry 1997;42:265-273
10. Carpenter WT, Conley RR, Buchanan RW, et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-832
11. Wilson WM. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am J Psychiatry 1996;153:951-952
12. Grace J, Bullus SB, Raulin ML, et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Serv 1996;47:41-45
13. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-815
14. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995:17:402-412
15. Tollefson GD, Beasely CM, Tran PV, et al. Olanzapine and negative symptoms: a path analysis. Am J Psychiatry 1997;154:466-472
16. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997;17:478-484
17. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997;17:472-477
18. Lieberman JA, Jody D, Geisler S, et al. Time course and biological predictors of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-376
19. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993:162:38-42
20. Marder SR, Kane JM, Schooler NR, et al. Effectiveness of clozapine in treatment resistant schizophrenia [abstract]. Schizophr Res 1997;24:187
21. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Pscyhiatr Scand 1992;85:295-305
22. Kronig MH, Loebel AD, Mendelowitz A, et al. Risperidone for treatment refractory schizophrenia. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 25, 1994; Philadelphia, Pa. Abstract NR355:148
23. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
24. Negron AE, Liederman EA, Parkadavil M, et al. A naturalistic outcome study of risperidone treatment among state hospital patients. Psychiatr Serv 1996;47:1118-1120
25. Buckley PF, Donenwirth K, Bayer KE, et al. Risperidone for treatment-resistant schizophrenia: initial clinical experience in a state hospital. Pharm Technol 1996;12:271-275
26. Bondolfi G, Bauman P, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998;155:499-504
27. Klieser E, Lehmann E, Kinzler E, et al. Randomized, double blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(suppl 1):45S-51S
28. Flynn SW, MacEwan GW, Altman S. et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 1998;31:25-29
29. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920
30. Shore D. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophr Bull 1995;21:333-336
31. Still DJ, Dorson PG, Crismon ML. et al Effects of switching inpatients wich treatment resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 1996;47:1382-1384
32. Weiden PJ, Aquila R. Dalheim L, et al. Switching antipsychotic medications. J Clin Psychiatry 1997;58(suppl 10):63-72
33. Lieberman JA, Saliz BL, Johns CA. et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
34. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9, suppl B):102-106
35. Tollefson GD, Beasely CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254
36. Wilkins JN. Pharmacotherapy of schizophrenia patients with co-morbid substance abuse. Schizophr Bull 1997;23:215-228
37. Bailey L, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33:177-181
38. Buckley PF, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:354-359
39. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 1994;182:591-592
40. Frankenburg FR. Experience with clozapine in refractory psychotic illnesses. In: Standards of Care in Schizophrenia: Proceedings of a Consensus Conference. Washington, DC: Sandoz Pharmaceuticals Corporation; 1994:3-19
41. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 1994;151:959
42. Conley RB, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia With substance abuse [abstract]. Schizophr Res 1997;24:190
43. Maurizio F. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997:20:427-452
44. Wilson WH. Clinical review of clozapine treatment in state hospital. Hosp Community Psychiatry 1992;43:700-703
45. Volavka J, Zito J, Vitra J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13:287-289
46. Chiles J, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint in a state hospital. Hosp Community Psychiatry 1994;45:269-271
47. Ebrahim G, Gibier B, Gacano CB, et al. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994;45: 271-273
48. Buckley PF, Kausch O, Gardner G. Clozapine treatment of schizophrenia: implications for forensic psychiatry. J Clin Forensic Med 1995;2:9-16
49. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
50. Rabinowitz J, Avnon M, Rosenberg V. The effect of clozapine or physical and verbal aggression. Schizophr Res 1996;22:249-255
51. Czobor P. Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-249
52. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression [letter]. Am J Psychiatry 1995;152:1239
53. Buckley PF, Ibrahim ZY, Singer B, et al. Violence and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 1997;25:173-181
54. Katz I, Brecher M, Clyde C, et al. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia [abstract]. Schizophr Res 1998;29:145
55. Beasley CM, Sayler ME, Kiesler GM, et al. The influence of pharmacotherapy on self-directed and externally directed aggression in schizophrenia [abstract]. Schizophr Res 1998;29:28
56. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel: evidence for efficacy in the treatment of hostility and aggression [abstract]. Schizophr Res 1998;29:154
57. Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999; 60(suppl 1):4-6